Molecularly targeted therapies for glioma

Annals of Neurology

Volumn 66, Issue 6, 2009, Pages 717-729

  Yamanaka, Ryuya ^a   Saya, Hideyuki ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; CILENGITIDE; DASATINIB; DEPSIPEPTIDE; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LONAFARNIB; NIMOTUZUMAB; PROTEIN P53; RAPAMYCIN; ROMIDEPSIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VATALANIB; VORINOSTAT;

ACNE; AGE DISTRIBUTION; ANOREXIA; ARTHRALGIA; BONE PAIN; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DNA METHYLATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; EDEMA; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TRANSCRIPTION REGULATION;

ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; BRAIN NEOPLASMS; ENZYME INHIBITORS; GLIOMA; HUMANS; ISOSORBIDE DINITRATE; SIGNAL TRANSDUCTION;

EID: 73549096412     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21793     Document Type: Review

References (110)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;359:1011-1018.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-2578.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
4. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
5. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79-88.
6. Kleihues P, Burger PC, Aldape KD, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC Press; 2007:33-49.
7. Reifenberger G, Kros JM, Loiis DN, et al. Oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC Press; 2007:54-59
8. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-173.
9. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 2006;66:11502-11513.
10. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005;102: 5814-5819.
11. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
12. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992;89:4309-4313.
13. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64: 6892-6899.
14. Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 1990;87:8602-8606.
15. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288-2294.
16. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Nat Acad Sci U S A 1999;96:4240-4245.
17. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
18. Duerr EM, Rollbrocker B, Hayashi Y, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998;16: 2259-2264.
19. Kamijo T, Weber JD, Zambetti G, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998;95:8292-8297.
20. Pomerantz J, Schreiber-Agus N, Liégeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-723.
21. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-530.
22. Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53: 2736-2739.
23. Nakamura M, Watanabe T, Klangby U, et al. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-168.
24. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13: 1501-1512.
25. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004;9:58-67.
26. Sedlacek HH. Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000;59:435-476.
27. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31: 637-643.
28. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227-231.
29. Semba K, Kamata N, Toyoshima K, et al. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A 1985;82:6497-6501.
30. Hackel PO, Zwick E, Prenzel N, et al. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999;11:184-189.
31. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-142.
32. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006;8:67-78.
33. Brown PD, Krishnan S, Sarkaria J, et al. A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2008;26:2016.
34. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024.
35. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-887.
36. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187.
37. Combs SE, Schulz-Ertner D, Roth W, et al. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 2007;68:873-882.
38. Yang W, Wu G, Barth RF, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res 2008;14:883-891.
39. Combs SE, Heeger S, Haselmann R, et al. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol. BMC Cancer 2006;6:133.
40. Neyns B, Sadones J, Joosens E, et al. A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. Proc Am Soc Clin Oncol 2008; 26:2017.
41. Lassen U, Hasselbalch B, Sorensen M, et al. A phase II trial with cetuximab, bevacizumab, and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolamide. Proc Am Soc Clin Oncol 2008;26:2056.
42. Combs SE, Schulz-Ertner D, Hartmann C, et al. Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT) - Eudract number 2005-003911-63; NCT00311857. Proc Am Soc Clin Oncol 2008; 26:2077.
43. Bode U, Windelberg M, Massimino M, et al. Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. Proc Am Soc Clin Oncol 2008;26:2058.
44. Folkman J, Merler E, Abernathy C, et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133: 275-288.
45. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380.
46. Goldbrunner RH, Bendszus M, Wood J, et al. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004;55:426-432.
47. Conrad C, Friedman H, Reardon D, et al. A phase I/II trial of single-agent PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004;22:1512.
48. Reardon D, Friedman H, Yung WKA, et al. A phase I/II trial of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004;22:1513.
49. Sathornsumetee S, Rich JN, Vredenburgh JJ, et al. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for recurrent glioblastoma multiforme GBM. Proc Am Soc Clin Oncol 2007;25:2027.
50. Batchelor T, Sorensen AG, Ancukiewicz M, et al. A phase II trial of AZD2171(cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Proc Am Soc Clin Oncol 2007;25:2001.
51. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259.
52. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729.
53. Rich JN, Desajardins A, Sathornsumetee S, et al. Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma. Proc Am Soc Clin Oncol 2008;26:2022.
54. Sathornsumetee S, Vredenburgh JJ, Rich JN, et al. Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. Proc Am Soc Clin Oncol 2008;26: 13008.
55. Maron R, Vredenburgh JJ, Desjardins A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2008;26:2074.
56. De Groot JF, Wen PY, Lamborn K, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. Proc Am Soc Clin Oncol 2008;26:2020.
57. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143-5150.
58. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006;12:4899-4907.
59. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23:9359-9368.
60. Marosi C, Vedadinejad M, Haberler C, et al. Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R. Proc Am Soc Clin Oncol 2006;24: 1526.
61. Kirkpatrick JP, Rich JN, Vredenburgh JJ, et al. Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). Proc Am Soc Clin Oncol 2008;26:2057.
62. Yamada S, Bu XY, Khankaldyyan V, et al. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006;59:1304-1312.
63. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651-1657.
64. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide(EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma. Proc Am Soc Clin Oncol 2007;25:2000.
65. Reardon D, Fink K, Nabors B, et al. Phase IIa trial of cilengitide (EMD121974) single agent therapy in patients with recurrent glioblastoma (GBM): EMD 121974-009. Proc Am Soc Clin Oncol 2007;25:2002.
66. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53-62.
67. Marais R, Light Y, Paterson HF, et al. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997;272:4378-4383.
68. Khosravi-Far R, Der CJ. The Ras signal transduction pathway. Cancer Metastasis Rev 1994;13:67-89.
69. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006;24:3651-3656.
70. Gilbert MR, Gaupp P, Lin V, et al. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarasar, SCH66336) in recurrent glioblastoma. Proc Am Soc Clin Oncol 2006;24:1556.
71. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006;12:3935-3941.
72. Sathornsumetee S, Hjelmeland AB, Keir ST, et al. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res 2006;66:8722-8730.
73. Sawyers CL. Will kinase inhibitors have a dark side? N Engl J Med 2006;355:313-315.
74. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-5304.
75. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357-361.
76. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-349.
77. Ryan AJ, Wedge SR. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005;92(suppl 1):S6-S13.
78. Rich JN, Sathornsumetee S, Keir ST, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 2005;11:8145-8157.
79. de Boüard S, Herlin P, Christensen JG, et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007;9:412-423.
80. Chaskis C, Sadones J, Michotte A, et al. A phase II trial of sunitinib in patients with recurrent high-grade glioma. Proc Am Soc Clin Oncol 2008;26:13001.
81. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64: 7099-7109.
82. Nabors LB, Rosenfeld M, Chamberlain M, et al. A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). Proc Am Soc Clin Oncol 25;2058:2007.
83. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-421.
84. Koschny R, Holland H, Sykora J, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007;13:3403-3412.
85. Dicker A, Werner-Wasik M, Machtay M, et al. A phase I trial using the proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for high grade gliomas. Proc Am Soc Clin Oncol 2007;25:2061.
86. Fouladi M. Histone deacetylase inhibitors in cancer therapy. Cancer Invest 2006;24:521-527.
87. Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007;13:1045-1052.
88. Galanis E, Jaeckle KA, Maurer MJ, et al: N047B:NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2007;25:2004.
89. Wien PY, Puduvalli V, Kuhn J, et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NBBTC 04-03). Proc Am Soc Clin Oncol 2007;25:2039.
90. Das CM, Aguilera D, Vasquez H, et al. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007;85:159-170.
91. Hagihara N, Walbridge S, Olson AW, et al. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res 2000;60:230-234.
92. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003;65:3-13.
93. Kunwar S, Prados MD, Chang SM, et al. Cintredekin Besudotox Intraparenchymal Study Group. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25:837-844.
94. Bogdahn U, Hau P, Olyushin V, et al. Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: results of a phase IIb study. Proc Am Soc Clin Oncol 2008;26:2018.
95. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-290.
96. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006;12:860-868.
97. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006;67:156-158.
98. Friedman HS, Desjardins A, Vredenburgh JJ, et al. Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2008;26:2062.
99. Phuphanich S, Rudnick J, Chu R, et al. A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2008;26:2088.
100. Robins HI, Wen PY, Chang SM, et al. Phase I study of erlotinib and CCI-779(temsirolimus) for patients with recurrent malignant gliomas (NABTC 04-02). Proc Am Soc Clin Oncol 2007;25:2057.
101. Hjelmeland AB, Lattimore KP, Wickman SW, et al. The combination of novel low molecular weight inhibitors of Raf (LBT 613) and TOR (RAD001, everolimus) decreases glioma proliferation and invasion. Neuro Oncol 2006;8:412.
102. Kim S, Dougherty ER, Shmulevich I, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther 2002;1:1229-1236.
103. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613-6625.
104. Rich JN, Hans C, Jones B, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 2005;65:4051-4058.
105. Yamanaka R, Arao T, Yajima N, et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006;25:5994-6002.
106. Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007;96:1155-1158.
107. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000;97:14720-14725.
108. Kondo T, Setoguchi T, Taga T. Persistence of a small sub-population of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 2004;101:781-786.
109. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
110. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004;23: 9392-9400.